Skip to main content
. 2022 Apr 12;304(1):228–237. doi: 10.1148/radiol.212426

Figure 3:

Kaplan-Meier survival curves show the comparison of patients with high (enhancing tumor volume [ETV] ≥65 cm3 and enhancing tumor burden [ETB] ≥4%) and low tumor burden (ETV <65 cm3 and ETB <4%) in (A, B) all patients (the Barcelona Clinic Liver Cancer [BCLC] B + C group), (C, D) only patients with BCLC B tumors, and (E, F) only patients with BCLC C tumors.

Kaplan-Meier survival curves show the comparison of patients with high (enhancing tumor volume [ETV] ≥65 cm3 and enhancing tumor burden [ETB] ≥4%) and low tumor burden (ETV <65 cm3 and ETB <4%) in (A, B) all patients (the Barcelona Clinic Liver Cancer [BCLC] B + C group), (C, D) only patients with BCLC B tumors, and (E, F) only patients with BCLC C tumors.